Camp4 Therapeutics Corporation (CAMP)
| Market Cap | 69.66M |
| Revenue (ttm) | 3.01M |
| Net Income (ttm) | -51.78M |
| Shares Out | 20.16M |
| EPS (ttm) | -3.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 247,000 |
| Open | 3.230 |
| Previous Close | 3.030 |
| Day's Range | 3.230 - 3.460 |
| 52-Week Range | 1.305 - 12.300 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 13.40 (+287.84%) |
| Earnings Date | Nov 20, 2025 |
About CAMP
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was inco... [Read more]
Financial Performance
In 2024, Camp4 Therapeutics's revenue was $652,000, an increase of 86.29% compared to the previous year's $350,000. Losses were -$51.79 million, 5.07% more than in 2023.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CAMP stock is "Buy." The 12-month stock price target is $13.4, which is an increase of 287.84% from the latest price.
News
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regul...
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $5...
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targetin...
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting...
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic...
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D.
CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
CAMP4 to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense ...
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotid...
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeuti...
CAMP4 Reports Third Quarter 2024 Financial Results
- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q...
CAMP4 Analyst Highlights Rare Disease Platform Potential
In October, CAMP4 Therapeutics Corporation CAMP priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million in gross proceeds.
CAMP4 Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting th...
Camp4 Therapeutics Targets IPO On Early Positive Results
Camp4 Therapeutics is seeking $75 million in an IPO to fund the advancement of its clinical-stage biopharma programs targeting genetic disorders. CAMP's lead candidate, CMP-CPS-001, has shown positive...
Genetic disease biotech CAMP4 Therapeutics files for a $75 million IPO
CAMP4 Therapeutics, a clinical-stage biotech developing RNA-based therapies to target genetic diseases, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
Kaiser Permanente-backed biopharma CAMP4 files for US IPO
CAMP4 Therapeutics, a biopharmaceutical firm backed by healthcare giant Kaiser Permanente, filed for an initial public offering in the United States on Friday.
CAMP4 Therapeutics IPO Registration Document (S-1)
CAMP4 Therapeutics has filed to go public with an IPO on the NASDAQ.
CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders
CAMP4 Therapeutics, a clinical-stage biotechnology company developing a pipeline of regulatory...